Three developments investors should carry into the week: capital moving into women’s-health diagnostics and devices, regulatory scrutiny shaping enormous diagnostic opportunities, and biotechnology materially outperforming the broader market.
Women’s Health Broadens, FDA Scrutiny Rises and Biotech Breaks Out
The Daily Capital Briefing — 9 August 2026
Keep reading with a 7-day free trial
Subscribe to The Billion Dollar Blindspot to keep reading this post and get 7 days of free access to the full post archives.